982 California job cuts precede Actavis, Allergan merger
This article was originally published in Scrip
Before the quickly negotiated $66bn acquisition of Allergan by Actavis to thwart an unwanted deal proposed by Valeant Pharmaceuticals, Allergan began executing its well-known plan to cut jobs in California and Actavis had its own layoffs under way in the Golden State.
You may also be interested in...
Allergan is working on a plan to reduce costs now that Restasis generics could hit the US market in 2018, but the company said sales growth for other drugs coupled with new product launches will boost revenue even if the dry eye drug loses its blockbuster status.
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.